Drug Search Results
More Filters [+]

Ketotifen

Alternative Names: ketotifen, allergy eye, allergy eye drops, ketotifeno, zaditen, zaditor, alaway, children's alaway
Latest Update: 2024-01-17
Latest Update Note: News Article

Product Description

Ketotifen is a type of asthma medication which, when taken every day and used along with other antiasthma medications, may reduce the frequency, severity, and duration of asthma symptoms or attacks in children. It may also lead to a reduction in daily requirements of other antiasthma medications. Ketotifen is not effective for the prevention or treatment of acute asthma attacks. Ketotifen works by inhibiting certain substances in the body that are known to cause inflammation and symptoms of asthma.

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Ophthalmic

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Bausch & Lomb
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ketotifen

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Conjunctivitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT05591755

P3

Completed

Conjunctivitis, Allergic

2023-08-04

56%

NCT05579730

P3

Completed

Conjunctivitis, Allergic

2023-07-22

56%

Recent News Events